Goal hub

Precision Fat Loss & Metabolic Reset

Labeled incretin and dual-agonist pens (STEP, SURMOUNT) versus research cakes, plus GHRH VAT math. Percentages are branded-trial numbers, not a compounded vial.

Full stacking map, tiers, and monitoring notes live on the protocol page — this hub only lists the compounds already named for this goal.

Open full protocolAll goals

Compounds on this goal

Tirzepatide

glp1

Dual GLP-1/GIP receptor agonist demonstrating 20.9% weight loss at 15mg in SURMOUNT-1 (n=2,539). Head-to-head superiority over semaglutide confirmed in SURMOUNT-5 with 20.2% vs 13.7% weight reduction at 72 weeks.

Open peptide leaf →

Semaglutide

glp1

Foundational GLP-1 agonist with the most extensive safety dataset. STEP 1 trial (n=1,961) demonstrated 14.9% weight loss vs 2.4% placebo at 68 weeks. STEP 5 confirmed durability with 15.2% at 104 weeks.

Open peptide leaf →

Tesamorelin

gh_secretagogue

FDA-approved GHRH analog achieving 15–18% reduction in visceral adipose tissue (VAT) in clinical trials. Uniquely targets deep organ fat via GH-axis without additive GI side effects from incretins.

Open peptide leaf →

MariTide

glp1

Amgen investigational monthly-class GIPR-antagonist / GLP-1 agonist conjugate (AMG 133). Pipeline literacy — not a Wegovy twin and not a research cake.

Open peptide leaf →

Amycretin

glp1

Novo investigational dual amylin/GLP-1 agonist. Not CagriSema. Oral and injectable programs are separate exposures.

Open peptide leaf →

Tesofensine

glp1

Oral monoamine reuptake inhibitor studied for obesity. Not a peptide and not a GLP-1. Adjacent in community plateau talk — that is not a labeled stack.

Open peptide leaf →

Evidence note on this goal

Protocol evidence level (from existing goal data): Strong

  • Weight regain is expected upon discontinuation - STEP 4 showed 6.9% regain over 48 weeks after stopping semaglutide
  • Long-term cardiovascular outcome data for tirzepatide still emerging (SURPASS-CVOT ongoing)
  • Retatrutide is not yet FDA-approved; Phase 3 TRIUMPH program is underway
  • Most trials exclude BMI >50; efficacy in severe obesity less characterized